The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
913
LUSVERTIKIMAB, A FIRST IN CLASS IL7 RECEPTOR ANTAGONIST, IN MODERATE TO SEVERE ULCERATIVE COLITIS: RESULTS OF A MULTICCENTER RANDOMIZEDPLACEBO-CONTROLLED PHASE II STUDY
Date
May 5, 2025
Explore related products in the following collection: